Indole Compound Modulating RNA m6A Methylation in Hyperkeratosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for skin-related diseases, particularly those related to skin hyperkeratosis, are inadequate, and there are no methods for preventing or treating these conditions by regulating RNA m6A methylation.

Innovation Solution

An indole compound is developed to regulate RNA m6A methylation, which can be used for preventing and/or treating skin-related diseases such as skin hyperkeratosis by modulating the expression of specific proteins involved in RNA methylation pathways.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for skin hyperkeratosis, then symptoms can be temporarily alleviated, but the underlying cause cannot be addressed and no preventive effect is achieved

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidpreventive capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The compound performs preliminary action by regulating RNA m6A methylation before hyperkeratosis fully develops. By modulating m6A methylases, demethylases, and binding proteins, the compound prevents abnormal keratogenesis from occurring in the first place, rather than merely treating established conditions.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The compound acts as an intermediary by targeting the RNA m6A methylation pathway, which serves as a intermediate regulatory mechanism between genetic expression and keratinocyte differentiation. This intermediary approach allows control over the biological processes that lead to hyperkeratosis without directly interfering with skin structure.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of manufacture

If no specific treatment is developed, then existing skin diseases can only be managed symptomatically, but new therapeutic opportunities remain unexplored

Engineering Contradiction:

Improvetreatment availabilityVSAvoiddisease management efficacy

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The compound achieves parameter changes by modulating the activity levels of m6A methylases, demethylases, and binding proteins. By altering these biochemical parameters, the compound corrects the methylation imbalance that drives hyperkeratosis, transforming the disease state back to normal.

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If RNA m6A methylation is not targeted, then the root cause of hyperkeratosis remains unaddressed, but this therapeutic pathway remains unexploited

Engineering Contradiction:

Improvetherapeutic pathway coverageVSAvoidcause-specific treatment

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The invention extracts and isolates the RNA m6A methylation pathway as a specific therapeutic target. By focusing on this discrete biological mechanism, the compound can selectively regulate keratinocyte differentiation without affecting other skin functions, achieving precise cause-specific treatment.

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentEP4729510A1Indole compound, preparation method therefor and use thereof

Publication Date: 2026.04.22 SUZHOU MERNA THERAPEUTICS CO LTD

Figure 1~2
Figure 3~4
Figure 5

AI summary

A compound of formula I, or a stereoisomer, a tautomer, a solvate, a hydrate, a prodrug, a stable isotope derivative, and a pharmaceutically acceptable salt thereof is provided: The compound has activity in preventing and/or treating a skin-related disease.